MabCure, Inc. Files Provisional Patent in the U.S. for Ovarian Cancer Antibodies

Published: Aug 03, 2010

NEW YORK--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure’s tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women. The patent application covers a panel of MAbs, each of which is capable of diagnosing ovarian cancer, and several that can correctly distinguish between ovarian cancer and benign tumors.

Back to news